Taxus Liberté launched in Japan
This article was originally published in Clinica
Boston Scientific has launched its Taxus Liberté paclitaxel-eluting stent in Japan. The product was approved on January 28 by the Ministry of Health, Labor and Welfare, and reimbursement was granted yesterday by the National Health Insurance System. Around 1,300 medical centres perform cardiac catheterisation in Japan, with an estimated at 200,000 coronary stents implanted annually.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.